Son is an experienced US Food and Drug Administration (FDA) lawyer, having spent almost 14 years at the agency as associate chief counsel for enforcement, associate chief counsel for devices and combination products, and senior counsel.
Longboard Pharmaceuticals Announces $2.6 Billion Sale to Lundbeck
October 14, 2024
Cooley advised Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.
